Total Artificial Heart Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Summary
GlobalData's Medical Devices sector report, “Total Artificial Heart Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Total Artificial Heart pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
A Total Artificial Heart is a prosthetic device that is implanted into the body to replace the biological heart.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Total Artificial Heart under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Total Artificial Heart and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Total Artificial Heart under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
About GlobalData
Introduction
Total Artificial Heart Overview
Products under Development
Total Artificial Heart - Pipeline Products by Stage of Development
Table Figure 1: Total Artificial Heart - Pipeline Products by Stage of Development
Table Total Artificial Heart - Pipeline Products by Stage of Development
Total Artificial Heart - Pipeline Products by Territory
Table Figure 2: Total Artificial Heart - Pipeline Products by Territory
Table Total Artificial Heart - Pipeline Products by Territory
Total Artificial Heart - Pipeline Products by Regulatory Path
Table Figure 3: Total Artificial Heart - Pipeline Products by Regulatory Path
Table Total Artificial Heart - Pipeline Products by Regulatory Path
Total Artificial Heart - Pipeline Products by Estimated Approval Date
Table Figure 4: Total Artificial Heart - Pipeline Products by Estimated Approval Date
Table Total Artificial Heart - Pipeline Products by Estimated Approval Date
Total Artificial Heart - Ongoing Clinical Trials
Table Figure 5: Total Artificial Heart - Ongoing Clinical Trials
Table Total Artificial Heart - Ongoing Clinical Trials
Total Artificial Heart - Pipeline Products under Development by Companies
Total Artificial Heart Companies - Pipeline Products by Stage of Development
Table Total Artificial Heart Companies - Pipeline Products by Stage of Development
Total Artificial Heart - Companies Pipeline Products by Stage of Development
Table Total Artificial Heart - Companies Pipeline Products by Stage of Development
Total Artificial Heart Companies and Product Overview
Table BiVACOR Device - BiVACOR Total Artificial Heart Early Feasibility Study
Carmat SAS Company Overview
Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview
Table Carmat SAS Pipeline Products & Ongoing Clinical Trials Overview
Table Aeson - Product Status
Table Aeson - Product Description
Table Carmat SAS - Ongoing Clinical Trials Overview
Table Aeson - Multicentric Prospective Cohort Study in Patients with Irreversible Biventricular Heart Failure to Assess the Efficacy and Safety of Carmat TAH, Its Clinical Utility and Cost, as a Bridge to Transplantation
Cleveland Clinic Lerner College of Medicine Company Overview
Cleveland Clinic Lerner College of Medicine Pipeline Products & Ongoing Clinical Trials Overview
Table Cleveland Clinic Lerner College of Medicine Pipeline Products & Ongoing Clinical Trials Overview
Table Continuous-Flow Total Artificial Heart - Product Status
Table Continuous-Flow Total Artificial Heart - Product Description
Table Pediatric Continuous-Flow Total Artificial Heart - Product Status
Table Pediatric Continuous-Flow Total Artificial Heart - Product Description
University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview
Table University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview
Table Total Artificial Heart - Product Status(University of New South Wales)
Table Total Artificial Heart - Product Description(University of New South Wales)
University of Tokyo Company Overview
University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview
Table University of Tokyo Pipeline Products & Ongoing Clinical Trials Overview
Table Helical Flow Total Artificial Heart - Product Status
Table Helical Flow Total Artificial Heart - Product Description
Total Artificial Heart- Recent Developments
Feb 20, 2024: Revolutionary Artificial Heart a Lifeline for Heart Failure Patients
Feb 20, 2024: BiVACOR Receives $13 Million to Support Clinical Trials for the Company's Total Artificial Heart
Feb 06, 2024: Realheart Appoints Andreas Hultdin as Interim CFO Following the Resignation of Jonas Caspari Bark
Feb 05, 2024: Syncardia Systems Announces Publication of Patent Application Covering Innovative Total Artificial Heart Design
Jan 15, 2024: CARMAT Achieves a Pivotal Year in 2023 by Reaching the Milestone of 50 Implants of the Aeson Artificial Heart and Presents Its Development Prospects
Dec 28, 2023: Carmat Announces a Software Enhancement which Significantly Improves the Safety Profile of its Aeson Artificial Heart
Dec 27, 2023: BiVacor Names Axonics CEO as Chair of its Board
Dec 11, 2023: Carmat Announces the First Implant of the Aeson Artificial Heart in a Patient Suffering from a Cardiac Tumor
Nov 30, 2023: BiVACOR wins IDE to start first-in-human study for artificial heart
Nov 29, 2023: magAssist Attended 2023 ISMCS to Showcase its Next-Gen Medical Solutions that Improve Treatment Outcomes of Critical Heart Diseases
Nov 21, 2023: National Heart Centre Singapore partners Mede
Nov 16, 2023: Scandinavian Real Heart: Interim Report July to September 2023
Nov 13, 2023: Realheart Provides an Update on the Development and Commercialization of Its Artificial Heart
Nov 01, 2023: Realheart has Successfully Established a Novel Test System to Evaluate Hemolysis of its Total Artificial Heart
Sep 25, 2023: CARMAT Reports its 2023 Half-Year Results and Provides an Update on its Strategic Progress
Sep 05, 2023: First Patient With Nyokassist Interventional Ventricular Assist Device: Dr. Junbo Ge's Team Successfully Completed the First High-Risk PCI Treatment Supported by the New Generation of Interventional VAD
Aug 30, 2023: Stuart McConchie Appointed Adjunct Board Member to Realheart
Aug 24, 2023: Scandinavian Real Heart Announces Interim Report 2023
Aug 23, 2023: Realheart's CEO to Speak at China Heart Congress
Aug 22, 2023: magAssist's ventricular pump scores FDA breakthrough designation
Aug 10, 2023: Magnus Ohman Appointed Adjunct Board Member to Realheart
Jul 11, 2023: SynCardia Updates Total Artificial Heart Labeling with Real World Data
Jun 28, 2023: Realheart Gets Go-Ahead for International Trademark Protection
Jun 15, 2023: Cardiac Surgeon Dilek Gursoy Speaks About Realheart's Artificial Heart at Impact LECH
Jun 14, 2023: Scandinavian Real Heart Announces Bulletin from the Annual General Meeting held on 14 June 2023
Jun 08, 2023: Realheart Part of Vinnova Project for Cordless TAH Technology
May 24, 2023: Realheart Releases the Annual Report for 2022
May 03, 2023: Scientists at Scandinavian Real Heart and at the University of Bath Publish the World's First Computer Simulation Method for Dual Mechanical Heart Valves in Series